Our data provide support for combining anti-angiogenic therapies to achieve a more effective treatment response; and specifically warrant clinical investigation of anti-Dll4 therapies alone and in combination with VEGF targeting agents for the treatment of ccRCC. Here, DLL4 is linked to nonpapillary renal cell carcinoma.